Onxeo
Develops precision-guided therapies for complex and underserved diseases.
ALONX | PA
Overview
Corporate Details
- ISIN(s):
- FR0010095596 (+3 more)
- LEI:
- 96950018AS30IUG0V528
- Country:
- France
- Address:
- 49 BOULEVARD DU GENERAL MARTIAL VALIN, 75015 PARIS
- Website:
- https://www.onxeo.com/
- Sector:
- Manufacturing
Description
Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-06 17:06 |
Inside Information / Other news releases
|
English | 245.0 KB | ||
| 2025-05-06 17:06 |
Informations privilégiées / Autres communiqués
|
French | 247.1 KB | ||
| 2025-03-19 15:27 |
Inside Information / Other news releases
|
English | 146.6 KB | ||
| 2025-03-19 12:30 |
Informations privilégiées / Autres communiqués
|
French | 192.3 KB | ||
| 2025-03-19 12:30 |
Inside Information / Other news releases
|
English | 257.6 KB | ||
| 2025-03-03 17:35 |
Informations privilégiées / Autres communiqués
|
French | 274.6 KB | ||
| 2025-03-03 17:35 |
Inside Information / Other news releases
|
English | 207.6 KB | ||
| 2024-11-15 08:00 |
Inside Information / Other news releases
|
English | 132.0 KB | ||
| 2024-11-15 08:00 |
Informations privilégiées / Autres communiqués
|
French | 194.5 KB | ||
| 2024-09-30 22:40 |
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
|
French | 1.7 MB | ||
| 2024-09-30 22:40 |
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
|
English | 2.1 MB | ||
| 2024-09-30 22:40 |
Inside Information: News release on accounts, results
|
English | 387.9 KB | ||
| 2024-09-30 22:40 |
Inside Information: News release on accounts, results
|
French | 373.1 KB | ||
| 2024-09-30 07:00 |
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 213.4 KB | ||
| 2024-09-30 07:00 |
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 276.8 KB |
Automate Your Workflow. Get a real-time feed of all Onxeo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Onxeo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Onxeo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-09 | N/A | Other | Other | 17,857,143 | 5,000,000.04 EUR |
| 2023-06-09 | N/A | Other | Other | 7,142,857 | 1,999,999.96 EUR |
Peer Companies
%20LTD/other/Cuprina_Holdings_Cayman_LTD-logo.png){kind=logo}
